Funding from the Biomedical Advanced Research and Development Authority (BARDA) is expected to support late-stage development and licensure of a pre-pandemic vaccine targeting the H5 influenza virus.
Moderna Receives $176 Million Biomedical Advanced Research and Development Authority Award to Advance Development of mRNA-Based Influenza Vaccine
Leave a comment
